Corona Remedies IPO: A Detailed Analysis
Corona Remedies, a pharmaceutical company, recently launched its shares on the stock market. The initial reaction was very positive. Shares opened significantly higher than the price set before the IPO, indicating strong investor interest.
Key Points
- Shares opened at a 38% premium, exceeding initial estimates.
- Investors bid for 137 times more shares than offered.
- Qualified Institutional Buyers heavily oversubscribed their shares.
- The IPO raised ₹655.37 crore through share sales.
- Existing shareholders sold their stake in the public offering.
- The company didn’t receive any new investment from the IPO.
The company’s shares started trading at ₹1,470 on the NSE and ₹1,452 on the BSE, a substantial premium of ₹408 and ₹390 respectively. This means investors were willing to pay more than the initially planned price. This initial strength is often seen as a good sign for a company’s future growth.
Before the IPO, investors were already excited about Corona Remedies’ shares, which were trading in the “grey market”—an unofficial market where shares are bought and sold before they are listed. These unlisted shares were priced at around ₹1,404.5, suggesting a “grey market premium” of ₹342.5, or 32.23% above the IPO price. This further boosted investor confidence.
The IPO itself was a huge success. Investors showed immense interest, placing bids for 626.54 million shares, compared to the 4.57 million shares the company offered. Institutional investors (QIBs) were particularly enthusiastic, buying more shares than they were allotted. Retail investors also contributed, but to a lesser extent.
Corona Remedies successfully raised ₹655.37 crore through the sale of shares. The IPO was structured as an “Offer for Sale” (OFS), where existing shareholders decided to sell their holdings. The price band for the IPO was set between ₹1,008 and ₹1,062 per share, and the sale period lasted from December 8th to December 10th. Shares were finally allocated on December 11th.
The IPO was managed by several leading investment banks: Bigshare Services was the registrar, and JM Financial, IIFL Capital Services, and Kotak Mahindra Capital Company acted as the lead managers. Key shareholders selling their shares included Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta, Dipabahen Niravkumar Mehta, and Brinda Ankur Mehta, as well as Sepia Investments, Anchor Partners, and Sage Investment Trust.
Ultimately, a strong IPO debut sets a positive foundation for Corona Remedies’ future performance.
